Racotumomab

N/A

Report date: 2022/01/14 13:23:58
First In Class

Base Information

Drug NameRacotumomab
Drug Alias NameVaxira1E10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulantsAnti-GM3
TargetsG(M3) Ganglioside
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungRetinoblastomaNeuroblastoma +[6] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2013/01/01
Country/TerritorySingaporeThailandPhilippines +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCenter Of Molecular Immunology
China Registration ClassN/A

Develop Information

Active CompaniesLaboratorio Elea Phoenix Sa
Inactive CompaniesRecombio Sl
Active IndicationsCarcinoma, Non-Small-Cell LungNeuroblastoma
Inactive IndicationsRetinoblastomaGliomaSarcoma, Ewing +[4] 

Other Information

ATC CodeL01XC
Related LinksWikipedia